Fig. 4From: Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trialKaplan–Meier plots of overall survival (OS), event-free survival (EFS) and disease-free survival (DFS) by ELN (2022) prognostic risk A OS. B EFS. C DFSBack to article page